PMID- 35154153
OWN - NLM
STAT- MEDLINE
DCOM- 20220314
LR  - 20220314
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Killer Cell Immunoglobulin-Like Receptor Haplotype B Modulates Susceptibility to 
      EBV-Associated Classic Hodgkin Lymphoma.
PG  - 829943
LID - 10.3389/fimmu.2022.829943 [doi]
LID - 829943
AB  - Tumor cells of classic Hodgkin lymphoma (cHL) are derived from antigen presenting 
      B cells that are infected by Epstein Barr virus (EBV) in ~30% of patients. 
      Polymorphic Killer cell immunoglobulin-like receptors (KIRs) expressed on NK 
      cells interact with human leukocyte antigen (HLA) class I and play a key role in 
      immune surveillance against virally infected cells and tumor cells. We 
      investigated the effect of KIR types on cHL susceptibility overall (n=211) and in 
      EBV-stratified subgroups using the Dutch GoNL cohort as controls (n=498). The 
      frequency of the KIR haplotype B subgroup was significantly different between 
      EBV+ and EBV- cHL patients (62% vs. 77%, p=0.04) and this difference was more 
      pronounced in nodular sclerosis (NS) cHL (49% vs. 79%, p=0.0003). The frequency 
      of KIR haplotype B subgroup was significantly lower in EBV+ NS cHL compared to 
      controls (49% vs. 67%, p=0.01). Analyses of known KIR - HLA interaction pairs 
      revealed lower carrier frequencies of KIR2DS2 - HLA-C1 (29% vs. 46%, p=0.03) and 
      KIR2DL2 - HLA-C1 (29% vs. 45%, p=0.04) in EBV+ NS cHL patients compared to 
      controls. Carriers of the KIR haplotype B subgroup are less likely to develop 
      EBV+ NS cHL, probably because of a more efficient control over EBV-infected B 
      cells.
CI  - Copyright (c) 2022 Jiang, Nolte, Hepkema, Stulp, van den Berg and Diepstra.
FAU - Jiang, Peijia
AU  - Jiang P
AD  - Department of Pathology and Medical Biology, University Medical Center Groningen, 
      University of Groningen, Groningen, Netherlands.
FAU - Nolte, Ilja M
AU  - Nolte IM
AD  - Department of Epidemiology, University Medical Center Groningen, University of 
      Groningen, Groningen, Netherlands.
FAU - Hepkema, Bouke G
AU  - Hepkema BG
AD  - Department of Laboratory Medicine, University Medical Center Groningen, 
      University of Groningen, Groningen, Netherlands.
FAU - Stulp, Marijke
AU  - Stulp M
AD  - Department of Laboratory Medicine, University Medical Center Groningen, 
      University of Groningen, Groningen, Netherlands.
FAU - van den Berg, Anke
AU  - van den Berg A
AD  - Department of Pathology and Medical Biology, University Medical Center Groningen, 
      University of Groningen, Groningen, Netherlands.
FAU - Diepstra, Arjan
AU  - Diepstra A
AD  - Department of Pathology and Medical Biology, University Medical Center Groningen, 
      University of Groningen, Groningen, Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220127
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (KIR2DL2 protein, human)
RN  - 0 (KIR2DS2 protein, human)
RN  - 0 (Receptors, KIR)
RN  - 0 (Receptors, KIR2DL2)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - B-Lymphocytes/immunology
MH  - Epstein-Barr Virus Infections/*immunology
MH  - Female
MH  - Haplotypes/immunology
MH  - Herpesvirus 4, Human/*immunology
MH  - Hodgkin Disease/*immunology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Receptors, KIR/*immunology
MH  - Receptors, KIR2DL2/*immunology
MH  - Young Adult
PMC - PMC8828906
OTO - NOTNLM
OT  - CHL
OT  - EBV
OT  - HLA class I
OT  - KIR
OT  - NK cells
OT  - susceptibility
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/02/15 06:00
MHDA- 2022/03/15 06:00
PMCR- 2022/01/01
CRDT- 2022/02/14 05:30
PHST- 2021/12/06 00:00 [received]
PHST- 2022/01/07 00:00 [accepted]
PHST- 2022/02/14 05:30 [entrez]
PHST- 2022/02/15 06:00 [pubmed]
PHST- 2022/03/15 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.829943 [doi]
PST - epublish
SO  - Front Immunol. 2022 Jan 27;13:829943. doi: 10.3389/fimmu.2022.829943. eCollection 
      2022.